Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 01 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-4.63 Insider Own10.21% Shs Outstand70.77M Perf Week4.52%
Market Cap802.53M Forward P/E- EPS next Y-3.76 Insider Trans192.44% Shs Float63.54M Perf Month-30.64%
Income-286.25M PEG- EPS next Q-0.89 Inst Own110.07% Short Float / Ratio16.65% / 10.09 Perf Quarter-58.22%
Sales0.00M P/S- EPS this Y-0.14% Inst Trans-1.11% Short Interest10.58M Perf Half Y-56.83%
Book/sh6.82 P/B1.66 EPS next Y16.09% ROA-51.35% Target Price34.10 Perf Year-48.73%
Cash/sh7.30 P/C1.55 EPS next 5Y- ROE-62.89% 52W Range9.56 - 31.46 Perf YTD-43.69%
Dividend- P/FCF- EPS past 5Y-66.20% ROI-54.52% 52W High-63.95% Beta1.58
Dividend %- Quick Ratio8.97 Sales past 5Y-25.00% Gross Margin- 52W Low18.62% ATR0.90
Employees156 Current Ratio8.97 Sales Q/Q- Oper. Margin0.00% RSI (14)39.36 Volatility5.77% 9.24%
OptionableYes Debt/Eq0.09 EPS Q/Q17.88% Profit Margin- Rel Volume0.53 Prev Close11.25
ShortableYes LT Debt/Eq0.09 EarningsNov 06 BMO Payout- Avg Volume1.05M Price11.34
Recom1.36 SMA20-0.71% SMA50-28.21% SMA200-47.48% Volume558,717 Change0.80%
Date Action Analyst Rating Change Price Target Change
Nov-08-23Downgrade Wedbush Outperform → Neutral $38 → $12
Nov-07-23Downgrade Leerink Partners Outperform → Market Perform $15
Jul-12-22Initiated Cowen Outperform
Apr-06-22Initiated Wells Fargo Overweight $67
Oct-07-21Resumed Jefferies Buy $120
Sep-30-21Initiated Stifel Buy $84
Sep-29-21Initiated Oppenheimer Outperform $90
May-21-21Initiated UBS Buy $91
Jan-20-21Initiated Wedbush Outperform $65
Sep-29-20Initiated Cantor Fitzgerald Overweight $44
Dec-01-23 05:39PM
Nov-13-23 09:03PM
Nov-09-23 07:00AM
Nov-06-23 07:13PM
04:52PM Loading…
Nov-01-23 04:52PM
Oct-07-23 05:00AM
Oct-02-23 04:27PM
Sep-14-23 01:02AM
Sep-06-23 07:00AM
Sep-01-23 04:37PM
Aug-09-23 07:00AM
Aug-01-23 04:28PM
Jun-15-23 06:01AM
06:00AM Loading…
Jun-06-23 06:00AM
Jun-02-23 02:34PM
May-26-23 12:33PM
May-25-23 05:38PM
May-23-23 07:00AM
May-12-23 09:55AM
May-10-23 07:00AM
Apr-26-23 10:00AM
Apr-17-23 09:00AM
Mar-01-23 07:00AM
Feb-13-23 07:00AM
Feb-01-23 05:00PM
Jan-17-23 09:18AM
05:00PM Loading…
Jan-03-23 05:00PM
Dec-08-22 09:55AM
Dec-01-22 05:00PM
Nov-09-22 07:00AM
Nov-08-22 07:01AM
Nov-01-22 05:38PM
Oct-24-22 07:00AM
Oct-17-22 07:00AM
Oct-03-22 05:32PM
Sep-27-22 04:01PM
Sep-19-22 07:00AM
Sep-12-22 07:00AM
Sep-01-22 05:00PM
Aug-31-22 07:00AM
Aug-26-22 12:00PM
Aug-16-22 09:55AM
Aug-10-22 04:39PM
Aug-09-22 04:01PM
Aug-03-22 07:00AM
Aug-01-22 05:10PM
Jun-27-22 07:00AM
Jun-14-22 09:10AM
Jun-01-22 07:00AM
May-31-22 07:00AM
May-26-22 09:48AM
May-21-22 09:48AM
May-18-22 04:01PM
May-16-22 07:28AM
May-05-22 07:00AM
Apr-27-22 10:17AM
Apr-19-22 09:35AM
Apr-11-22 04:01PM
Apr-08-22 01:00PM
Mar-29-22 07:00AM
Mar-22-22 07:00AM
Mar-09-22 04:01PM
Mar-08-22 04:30PM
Feb-24-22 07:00AM
Feb-03-22 07:00AM
Dec-22-21 10:15AM
Dec-21-21 12:03PM
Dec-14-21 11:15AM
Dec-02-21 07:00AM
Nov-17-21 11:35AM
Nov-10-21 07:00AM
Nov-09-21 07:00AM
Nov-08-21 10:07AM
Nov-03-21 11:26AM
Oct-25-21 12:04PM
Oct-05-21 11:28AM
Sep-13-21 07:00AM
Sep-09-21 07:00AM
Sep-02-21 07:00AM
Sep-01-21 07:00AM
Aug-12-21 07:00AM
Aug-04-21 07:00AM
Aug-02-21 07:30AM
Jul-28-21 01:15PM
Jul-01-21 04:01PM
Jun-29-21 06:54AM
Jun-28-21 09:09PM
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Blackwell KimberlyChief Executive OfficerNov 13Buy10.295,00051,448254,800Nov 13 05:24 PM
Johnson David MichaelDirectorNov 10Buy9.8817,000167,943144,389Nov 13 05:24 PM
Brownstein CarrieChief Medical OfficerOct 04Sale19.5010,628207,298105,685Oct 06 07:19 PM
Bunker Kevin D.Chief Scientific OfficerOct 04Sale19.506,068118,355859,089Oct 06 07:19 PM
Epperly Melissa B,Chief Financial OfficerOct 04Sale19.505,482106,926387,691Oct 06 07:18 PM
Skvarka JanDirectorSep 11Sale25.055,000125,23847,970Sep 13 04:11 PM
Matrix Capital Management Comp10% OwnerJun 20Buy22.664,760,000107,861,60013,959,973Jun 20 04:30 PM
Gallagher CamPresidentMay 31Sale26.2727,768729,506463,502May 31 09:10 PM
Bunker Kevin D.Chief Scientific OfficerMay 26Sale30.0280,0002,401,24815,000May 31 09:09 PM
Gallagher CamPresidentFeb 14Sale19.968,501169,706491,270Feb 14 07:09 PM
Bunker Kevin D.Chief Scientific OfficerFeb 14Sale19.986,500129,873865,157Feb 14 07:07 PM
Epperly Melissa B,Chief Financial OfficerFeb 14Sale19.985,227104,411392,048Feb 14 07:10 PM
Bunker Kevin D.Chief Scientific OfficerFeb 13Sale20.423,80777,756871,657Feb 14 07:07 PM
Gallagher CamPresidentFeb 13Sale20.423,33268,054499,771Feb 14 07:09 PM
Epperly Melissa B,Chief Financial OfficerFeb 13Sale20.422,62453,594397,275Feb 14 07:10 PM
Gallagher CamPresidentFeb 06Sale22.2710,000222,678503,103Feb 06 07:36 PM
Gallagher CamPresidentJan 17Sale24.1510,000241,515352,011Jan 18 05:15 PM
Gallagher CamPresidentJan 05Sale21.0210,000210,228362,011Jan 05 07:16 PM